Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial Drugs
DOI:
https://doi.org/10.3889/oamjms.2016.020Keywords:
Antibiotic, Urinary tract infection, uropathogensAbstract
Urinary tract infections (UTIs) are among the commonest types of bacterial infections. The antibiotic treatment for UTIs is associated with important medical and economic implications. Many different microorganisms can cause UTIs though the most common pathogens are E. coli and members of family Enterobacteriaceae. The knowledge of etiology and antibiotic resistance pattern of the organisms causing urinary tract infection is essential. The present study was undertaken to evaluate trends of antibiotic susceptibility of commonly isolated uropathogens using newer antimicrobial agents, prulifloxacin, fosfomycin (FOM) and doripenem. We conclude that maintaining a record of culture results and the antibiogram may help clinicians to determine the empirical and/or specific treatment based on the antibiogram of the isolate for better therapeutic outcome.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Foxman, B., K. L. Klemstine, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 2003; 13:144-150.
http://dx.doi.org/10.1016/S1047-2797(02)00272-7 DOI: https://doi.org/10.1016/S1047-2797(02)00272-7
Williams DH, Schaeffer AJ. Current concepts in urinary tract infections. Minerva Urol Nefrol. 2004; 56: 15-31.
PMid:15195028
Kunin CM. Urinary tract infections in females. Clin Infect Dis. 1994; 18:1-12.
http://dx.doi.org/10.1093/clinids/18.1.1 DOI: https://doi.org/10.1093/clinids/18.1.1
PMid:8054415
Patton JP, Nash DB, Abrutyn E. Urinary tract infections: Economic considerations. Medical clinics of North America. 1991;75:495-513. DOI: https://doi.org/10.1016/S0025-7125(16)30466-7
PMid:1996046
Kaem SJ, Perry CM. Prulifloxacin. Drugs. 2004; 64:2221-2234.
http://dx.doi.org/10.2165/00003495-200464190-00005 DOI: https://doi.org/10.2165/00003495-200464190-00005
Prats G, Roig C, Miro E, Navarro F, Mirelis B. In vitro activity of the active metabolites of Prulifloxacin (Af_3013) Compared with six other floroquinolones. Eur J lin Microbiol Infect Dis. 2002; 21:328-334.
http://dx.doi.org/10.1007/s10096-002-0709-1 DOI: https://doi.org/10.1007/s10096-002-0709-1
PMid:12072950
Montanari MP, Mingoia M, Varaldo PE. In vitroantibacterial activities of AF 3013, the active metabolite of Prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemotherap. 2001; 45:3616-3622.
http://dx.doi.org/10.1128/AAC.45.12.3616-3622.2001 DOI: https://doi.org/10.1128/AAC.45.12.3616-3622.2001
PMid:11709353 PMCid:PMC90882
Kahan FM, KAhan JS, Cassidy PJ, Knoop H. The mechanism of action of fosfomycin (Phosphomycin). Ann NY Acd Sci. 1974; 235:364-86.
http://dx.doi.org/10.1111/j.1749-6632.1974.tb43277.x DOI: https://doi.org/10.1111/j.1749-6632.1974.tb43277.x
Hendin D, Stapley EO, Jackson M et al. Phosphomycin, a new antibiotic produced by strains of Streptomyces. Science (New York, NY).1969; 166: 122-3.
http://dx.doi.org/10.1126/science.166.3901.122 DOI: https://doi.org/10.1126/science.166.3901.122
Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated actute bacterial cystitis and acute pylonephritis in women. Infectious Dis Society of America (IDSA). Clin Infect Dis. 1999; 29: 745-58.
http://dx.doi.org/10.1086/520427 DOI: https://doi.org/10.1086/520427
PMid:10589881
Anonymous. Doripenem (Doribax)- A new parenteral carbapenem. The medical letter. 2008; 50:1278:5-7.
Cheesbrough M. District Laboratory Practice in Tropical Countries. Part 2 © Monica Cheesbrough.Examination of urine and antimicrobial sensitivity testing, 2000:pp. 105–143.
Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: sixteenthinformational supplement. CLSI document M100-S16. Wayne, Pa: CLSI, 2006.
Carmignani G, Rose AFDe, Olivieri l, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of Adults with complicated urinary tract infections. Urologia International. 2005; 74:326-331.
http://dx.doi.org/10.1159/000084432 DOI: https://doi.org/10.1159/000084432
PMid:15897698
Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009;53(10):4508-10.
http://dx.doi.org/10.1128/AAC.00721-09 DOI: https://doi.org/10.1128/AAC.00721-09
PMid:19687248 PMCid:PMC2764175
Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013;17(11):e966-70.
http://dx.doi.org/10.1016/j.ijid.2013.04.005 DOI: https://doi.org/10.1016/j.ijid.2013.04.005
PMid:23742831
Gales AC, Azevedo HD, Cereda RF, Girardello R, Xavier DE. INVITA-A-DORI Brazilian Study Group. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study. Braz J Infect Dis. 2011; 15(6):513-20. DOI: https://doi.org/10.1590/S1413-86702011000600003
http://dx.doi.org/10.1016/S1413-8670(11)70244-6 DOI: https://doi.org/10.1016/S1413-8670(11)70244-6
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0